Skip to main content
. 2010 Nov 15;55(2):925–928. doi: 10.1128/AAC.00949-10

TABLE 2.

Routine laboratory results for patients

Patient Laboratory resulta
Creatinine (mg/dl) Urea (mg/dl) Bilirubin (mg/dl) AST (U/liter) ALT (U/liter) GGT (U/liter) PT (%) WBC (109 cells/liter) Hb (g/liter) PLT (109 cells/liter)
Baseline testing
    1 0.40 46.6 6.12 55 40 1,317 86 27.0 95 185
    2 0.88 69.7 11.00 60 149 686 70 10.6 77 106
    3 0.73 60.8 9.75 61 50 148 50 11.8 97 24
    4 1.47 83.2 0.95 20 40 480 90 7.1 99 21
    5 1.12 76.1 8.63 235 214 2,534 72 9.1 79 136
    6 0.68 81.1 1.14 33 22 232 76 4.5 89 21
    7 0.64 47.1 0.28 15 9 35 90 16.9 91 241
    8 0.92 62.0 0.93 50 40 433 77 5.2 91 296
Median 0.81 65.9 3.63 53 40 457 77 9.9 91 121*
Interquartile range 0.36 24.7 8.25 34 69 812 17 8.2 12 191
Final testing
    1 0.40 46.6 6.12 55 40 1,317 86 27.0 95 185
    2 1.99 106.7 9.29 221 109 1,129 67 13.5 84 15
    3 0.62 80.5 15.33 107 75 180 51 9.5 101 12
    4 0.98 57.1 3.45 43 66 338 89 7.0 74 18
    5 0.89 60.5 7.93 205 186 1,827 70 6.2 87 112
    6 1.53 183.1 0.46 31 20 209 108 3.1 73 28
    7 3.07 250.7 0.36 1,079 667 102 25 39.9 108 108
    8 2.45 100.5 1.00 56 29 656 82 6.6 88 177
Median 1.26 90.5 4.79 82 71 497 76 8.25 88 82*
Interquartile range 1.47 86.1 7.88 164 113 1,029 29 13.9 19 128
a

The results from routine laboratory tests on the first day of VRC treatment (baseline testing) and final routine laboratory test results are shown as follows: serum creatinine, normal range, 0.51 to 1.17 mg/dl; urea, normal range 18 to 55 mg/dl; plasma bilirubin, normal range, 0.00 to 1.29 mg/dl; aspartate aminotransferase (AST), normal range, 10 to 50 U/liter; alanine aminotransferase (ALT), normal range, 10 to 50 U/liter; γ-glutamyl transferase (GGT), normal range, 6 to 71 U/liter; prothrombin time (PT), normal range 70 to 130%; white blood cell (WBC) count, normal range, 4.0 × 109 to 10.0 × 109 cells/liter; hemoglobin (Hb), normal range, 120 to 177 g/liter; and platelet (PTL) count, normal range, 150 × 109 to 380 × 109 cells/liter. *, significant differences between the first and last testings (Wilcoxon matched-pairs test). No significant increases in liver and renal function tests were observed during VRC therapy. Since all patients were on sedoanalgesia, neurotoxicity of VRC could not be assessed.